The present disclosure relates to complexes comprising caffeine and tannic acid as well as emulsions and beverages comprising these complexes which slow the release of the caffeine. Also described are methods of preparing the complexes and emulsions and beverages comprising caffeine-tannic acid complexes.

The present disclosure relates to complexes comprising caffeine and tannic acid as well as emulsions and beverages comprising these complexes which slow the release of the caffeine. Also described are methods of preparing the complexes and emulsions and beverages comprising caffeine-tannic acid complexes.

A highly pure form of ferric citrate and an industrially viable and advantageous process for its preparation are described.

##STR00001##

A highly pure form of ferric citrate and an industrially viable and advantageous process for its preparation are described.

##STR00001##

Described herein is a liquid enzyme preparation containing component (a): at least one salt according to general formula (I)
(R.sup.2).sub.3N.sup.+—(CH.sub.2).sub.nC(R.sup.3)(R.sup.4)—(O—X).sub.m—O—C(O)—R.sup.1A.sup.−  (I) wherein n is selected from 1 to 12, m is selected from zero to 50, R.sup.1 is selected from the group consisting of methyl, ethyl, —CH(OH)—CH(OH)—COOH, CH(OH)—CH.sub.3, (E)-CH═CHCOOH, (Z)—CH═CHCOOH, —C.sub.6H.sub.5, para-HO—C.sub.6H.sub.4—, o,p-dihydroxyphenyl, and 3,4,5-triydroxyphenyl, R.sup.2 are same or different and selected from C.sub.1-C.sub.10-alkyl, phenyl, R.sup.3 and R.sup.4 are same or different and selected from hydrogen and C.sub.1-C.sub.4-alkyl, X is C.sub.2-C.sub.4-alkylen, and A.sup.− is an inorganic or organic counteranion,
component (b): at least one enzyme selected from hydrolases (EC 3),
and
optionally component (c): at least one compound selected from enzyme stabilizers different from component (a), preservatives, and surfactants.

The present invention relates to specific salts of (1S,5R)-(1α,5α,6α)-N-[1,1-dimethyl-2-[(3-methyl-2-pyridyl)oxy]ethyl]-3-azabicyclo[3.1.0]hexane-6-carboxamide, to pharmaceutical compositions comprising said salts, to methods of using said salts to treat physiological disorders, and to intermediates useful in the synthesis of the salts.

Provided are powder of a pure disilver hydrogen citrate-containing composition in powder form, having excellent solubility, and a method for easily obtaining the disilver hydrogen citrate-containing composition with high efficiency. In addition, provided are an antibacterial agent or antiviral agent, containing the disilver hydrogen citrate-containing composition, and a method for producing the same.

The method for producing a disilver hydrogen citrate-containing composition of the present invention includes the following processes (1) to (3): (1) preparing a reaction mixture containing a silver compound and citric acid, the reaction mixture having a pH of 2.0 to 5.5; (2) precipitating the disilver hydrogen citrate-containing composition from the reaction mixture; and (3) collecting the precipitated disilver hydrogen citrate-containing composition.

The present application pertains to methods for making alkali hydroxide, or alkali carbonates, or alkali bicarbonates, or alkaline-earth sulfates. In one embodiment, a material comprising an alkaline earth is converted to an alkaline earth sulfite or bisulfite and reacted with an alkali sulfate to form an alkaline earth sulfate and alkali sulfite or bisulfite. The alkali sulfite or bisulfite is converted into an alkali hydroxide, or an alkali carbonate, or an alkali bicarbonate. In another embodiment, ammonium carbonate or ammonium bicarbonate is reacted with an alkali sulfate, to form ammonium sulfate and an alkali carbonate or alkali bicarbonate. A material comprising an alkaline earth is converted to an alkaline earth sulfite or bisulfite and reacted with the ammonium sulfate to form an alkaline earth sulfate and ammonium sulfite or ammonium bisulfite. The ammonium sulfite or bisulfite is regenerated into ammonia, or ammonium hydroxide, or ammonium carbonate, or ammonium bicarbonate.

The present application pertains to methods for making alkali hydroxide, or alkali carbonates, or alkali bicarbonates, or alkaline-earth sulfates. In one embodiment, a material comprising an alkaline earth is converted to an alkaline earth sulfite or bisulfite and reacted with an alkali sulfate to form an alkaline earth sulfate and alkali sulfite or bisulfite. The alkali sulfite or bisulfite is converted into an alkali hydroxide, or an alkali carbonate, or an alkali bicarbonate. In another embodiment, ammonium carbonate or ammonium bicarbonate is reacted with an alkali sulfate, to form ammonium sulfate and an alkali carbonate or alkali bicarbonate. A material comprising an alkaline earth is converted to an alkaline earth sulfite or bisulfite and reacted with the ammonium sulfate to form an alkaline earth sulfate and ammonium sulfite or ammonium bisulfite. The ammonium sulfite or bisulfite is regenerated into ammonia, or ammonium hydroxide, or ammonium carbonate, or ammonium bicarbonate.

A benzodiazepine compound represented by formula I, or a salt thereof has an intravenous sedative anesthesia effect. The recovery quality of the compound is significantly improved compared with remimazolam in rat and mouse caudal venous anesthesia models. During anesthetization, the compound has a rapid onset, a short duration, a quick recovery and a good tolerance, can be used for anesthesia induction, anesthesia maintenance and day surgery anesthesia.

##STR00001##